---
title: Observational Study to Assess Genotypes/Phenotypes Correlations in Type-2 Diabetic Retinopathy
nct_id: NCT01228981
overall_status: COMPLETED
sponsor: Association for Innovation and Biomedical Research on Light and Image
study_type: OBSERVATIONAL
primary_condition: Type-2 Diabetic Retinopathy
countries: Portugal
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01228981.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01228981"
ct_last_update_post_date: 2016-04-25
last_seen_at: "2026-05-12T06:30:17.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Observational Study to Assess Genotypes/Phenotypes Correlations in Type-2 Diabetic Retinopathy

**NCT ID:** [NCT01228981](https://clinicaltrials.gov/study/NCT01228981)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 400
- **Lead Sponsor:** Association for Innovation and Biomedical Research on Light and Image
- **Collaborators:** University of Coimbra
- **Conditions:** Type-2 Diabetic Retinopathy
- **Start Date:** 2010-03
- **Completion Date:** 2013-03
- **CT.gov Last Update:** 2016-04-25

## Brief Summary

The purpose of this study is to characterize type 2 diabetic patients with initial alterations of diabetic retinopathy (DR) based on 3 different phenotypes previously identified and different patterns of progression in order to correlate this data with genetic information.

## Detailed Description

This study aims to to characterize type 2 diabetic patients with initial alterations of diabetic retinopathy (DR) based on three different phenotypes previously identified and different patterns of progression \[Lobo, 2004\] in order to correlate this data with genetic information (based on a list of candidate genes previously identified as being involved in DR).

The results of this study will be used exclusively for scientific purposes.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Type-2 diabetic subjects form the PTDC/SAU-OSM/72635/2006 clinical trial (early stages of non-proliferative retinopathy - level 30 to 35 ETDRS;. females or males; age over 18 years) with a signed Informed Consent for this study.

Exclusion Criteria:

* Cataract or other eye disease that may interfere with fundus examinations; Vitreous syneresis or posterior vitreous detachment; and Dilatation of the pupil \< 5 mm.
```

## Arms

- **Type-2 Diabetic Retinopathy**

## Primary Outcomes

- **Phenotypes of Diabetic Retinopathy progression.** _(time frame: June 2011)_

## Locations (1)

- AIBILI - Clinical Trials Center, Coimbra, Coimbra District, Portugal

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.aibili - clinical trials center|coimbra|coimbra district|portugal` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01228981.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01228981*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*